

SYNTHETIC STUDIES ON OXETANOCIN ANALOGS: SYNTHESIS OF  
OXETANOSYL C-NUCLEOSIDE,  
2-DEOXY-2-HYDROXYMETHYL- $\beta$ -D-ERYTHROOXETANOSYL MALEIMIDE


Tatsuya Watanabe, Shigeru Nishiyama, Shosuke Yamamura,\* Kuniki Kato,<sup>+</sup> Masashi Nagai<sup>+</sup>  
and Tomohisa Takita<sup>+</sup>

Department of Chemistry, Faculty of Science and Technology, Keio University  
Hiyoshi, Yokohama 223, Japan


<sup>+</sup> Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co. Ltd.  
3-31-12 Shimo, Kita-ku, Tokyo 115, Japan

**Summary:** Synthesis of oxetanosyl C-nucleoside similar to showdomycin, 2-deoxy-2-hydroxy-methyl- $\beta$ -D-erythrooxetanosyl maleimide has successfully been carried out starting from the potent intermediate of oxetanocin synthesis.


Related to a novel antiviral antibiotic oxetanocin (**1**),<sup>1</sup> our attention was focused on synthesis of its analogs and their biological activities. As a part of this investigation, we synthesized showdomycin-type C-nucleoside<sup>2</sup> carrying a four-membered ring sugar, oxetanose. We disclose herein our synthetic process of 2-deoxy-2-hydroxy-methyl- $\beta$ -D-erythrooxetanosyl maleimide (**2**).



**1** (OXETANOCIN)




**2**



SHOWDOMYCIN

When the known oxetane derivative (**3**)<sup>3</sup> was submitted to Grignard reaction (vinylmagnesium bromide, -50°C→ room temp.), the corresponding allyl alcohols (**4**) were obtained as ca. 2:1 mixture in 53% yield. The OH group in **4** was protected as *tert*-butyldimethylsiloxy ether (TBDMSCl, Imd.) to give **5**, which was converted into a mixture of methyl ester (**6**) in four steps. (1. cat. OsO<sub>4</sub>, 96%; 2. NaIO<sub>4</sub>, 83%; 3. KMnO<sub>4</sub>, 4. CH<sub>2</sub>N<sub>2</sub>, 54% in two steps) Removal of the TBDMS group (nBu<sub>4</sub>NF in THF, 83%) provided chromatographically separable alcohols (**7a** and **7b**) in quantitative yields, respectively. Oxidation of either alcohol with DMSO - Ac<sub>2</sub>O afforded the same  $\alpha$ -keto ester (**8**)<sup>4</sup> in high yield. However, on using tetrapropylammonium perruthenate (TPAP)<sup>5</sup> as oxidizing reagent, the reaction proceeded in entirely different way to afford a  $\beta$ -lactone (**9**) in 44% yield. Compound **8** thus obtained was treated with a phosphorane (**10**)<sup>6</sup> in CHCl<sub>3</sub> (room temp., 40



min) to yield a maleimide (**11**)<sup>4</sup> in 24% yield<sup>7</sup> via a simultaneous cyclization. In the final step, successful debenzoylation of **11** by a hydrogen transfer method (Pd-black in  $\text{HCOOH}$ - MeOH) provided the target **2**<sup>4</sup> in 28% yield.<sup>7</sup> To the best of our knowledge, this is the first synthesis of oxetanosyl C-nucleoside.

Bioassay data concerning antiviral activities will be published elsewhere.

#### REFERENCES

1. N. Shimada, S. Hasegawa, T. Harada, T. Tomisawa, A. Fujii, and T. Takita, *J. Antibiot.*, **39**, 1623 (1986); H. Nakamura, S. Hasegawa, N. Shimada, A. Fujii, T. Takita, and Y. Iitaka, *ibid.*, **39**, 1629 (1986).
2. S. Hanessian and A. Pernet, *Adv. Carbohydr. Chem. and Biochem.*, **33**, 111 (1976); G. Trummelitz and J. G. Moffatt, *J. Org. Chem.*, **38**, 1841 (1973); G. Just, T. J. Liak, M. Lim, P. Potvin, and Y. S. Tsantrizos, *Can. J. Chem.*, **58**, 2024 (1980).
3. S. Nishiyama, S. Yamamura, K. Kato, and T. Takita, *Tetrahedron Lett.*, **29**, 4739 (1988).
4. **8**: IR (film)  $1740\text{ cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  5.44 (1H, d,  $J = 7\text{ Hz}$ ). **11**:  $[\alpha]_{\text{D}}^{29} +41.2^\circ$  (c 0.78,  $\text{CHCl}_3$ ); IR (film)  $3250$ ,  $1780$  (sh.),  $1730$ , and  $1640\text{ cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  3.10 (1H, m), 3.57 (1H, dd,  $J = 4.2$ ,  $11.5\text{ Hz}$ ), 3.64 - 3.69 (2H, complex), 3.74 (1H, dd,  $J = 5.9$ ,  $10\text{ Hz}$ ), 4.54 - 4.62 (4H, complex), 4.91 (1H, m), 5.42 (1H, dd,  $J = 2.0$ ,  $6.8\text{ Hz}$ ), 6.61 (1H, t,  $J = 2.0\text{ Hz}$ ), 7.10 (1H, broad s), and 7.33 (10H, complex). **2**:  $^1\text{H NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  2.92 (1H, m), 3.61 (1H, dd,  $J = 4.6$ ,  $12.9\text{ Hz}$ ), 3.69 (1H, dd,  $J = 3.1$ ,  $12.9\text{ Hz}$ ), 3.76 (1H, dd,  $J = 4.6$ ,  $11.6\text{ Hz}$ ), 3.82 (1H, dd,  $J = 5.6$ ,  $11.6\text{ Hz}$ ), 4.75 (1H, m), 5.38 (1H, dd,  $J = 2.0$ ,  $7.1\text{ Hz}$ ), and 6.63 (1H, d,  $J = 2.0\text{ Hz}$ ).
5. W. P. Griffith, S. V. Ley, G. P. Whitcombe, and A. D. White, *J. Chem. Soc., Chem. Commun.*, **1987**, 1625.
6. S. Trippett and D. M. Walker, *J. Chem. Soc.*, **1959**, 3874.
7. The reaction condition has not yet been optimized.

(Received in Japan 17 January 1991)